NOTE 6 - INTANGIBLE ASSETS

Marketing Contacts

On September 17, 2009, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), whereby BioPharma became a wholly-owned subsidiary of the Company. Pursuant to the terms of the Merger Agreement, 4,500,000 shares of the Company's common stock were issued in exchange for all the outstanding common stock of BioPharma.

Prior to the Merger Agreement, BioPharma entered into a 50% joint venture with A&Z Pharmaceutical, LLC ("A&Z") to form Pharma Technology International, LLC ("Pharma Tech"). A&Z is a privately-held wholesale distributor of pharmaceuticals formed in 1997. A&Z's customer base includes tertiary hospitals, medical institutions, and governmental agencies located in the United States, South America, Europe and the Middle East.

Pharma Tech entered into a Distribution Agreement (the "Distribution Agreement") to market, distribute and sell the WCI wound care products in the Middle East through existing A&Z distribution channels. The agreement, which covers 20 countries throughout the Middle East and Northern Africa, requires Pharma Tech to sell a minimum of $500,000 of the products each year of the five year agreement to maintain the exclusive right to sell the products. The operations of Pharma Tech to date have been minimal, and although Pharma Tech placed orders with WCI during 2010 for sales of the CellerateRX product in Lebanon, the minimum sales amount was not obtained. Our recent experience with international markets indicates that the sales process is much lengthier than first anticipated. As a result, the impact on sales figures from the contacts in the Middle East can't be accurately evaluated until the sales team has had 24 months to work through the government regulations regarding the sale of medical products. Although other distributors are now able to sell the product in the region, the sales pipeline already developed by Pharma Tech in year one has resulted in additional sales in 2011.

As part of the BioPharma acquisition, the formula for a shingles based product was obtained which is only at the idea stage and no determination has been made as to whether the formula can be developed cost effectively into a product. According to the guidance in ASC Topic No. 805-20-25-1, identifiable assets should be recognized separately from goodwill and there was no value assigned to this formula.

The BioPharma transaction has been accounted for as a business combination based on the guidance in ASC Topic No. 805. The financial statements of BioPharma have been consolidated with those of the Company and an intangible asset was recorded in the amount of $4,187,815 or approximately $.93 per common share issued on the date of acquisition. The value of the intangible asset assigned to the marketing contacts recorded by the Company is based on Level 3 input to our valuation methodology, which consists of models with significant unobservable market parameters. We utilized a discounted cash flow analysis based on sales projections from the Distribution Agreement adjusted for the associated costs. According to ASC Topic No. 805-20-55-27, a customer relationship acquired in a business combination that does not arise from a contract may be an identifiable asset separate from goodwill. The estimated useful life of the intangible asset is ten years based on the automatic renewable five year term of the Distribution Agreement. The amount amortized for the nine months ended September 30, 2011 was $314,087 resulting in a balance of $837,563 in accumulated amortization as of September 30, 2011. The balance of the intangible asset, net of accumulated amortization, is $3,350,252 as of September 30, 2011.

Patent

On September 29, 2009, the Company entered into an Asset Purchase Agreement (the "Agreement"), whereby the Company acquired a patent from Resorbable Orthopedic Products, LLC, a New Jersey limited liability company ("Resorbable NJ") in exchange for 500,000 shares of the Company's common stock and the assumption of a legal fee payable in the amount of $47,595 which is related to the patent. Based on the guidance in ASC Topic No. 350-30, the patent was recorded as an intangible asset of $462,715, or approximately $.93 per share, plus $47,595 for the assumed liability. The intangible asset is being amortized over an estimated ten year useful life. The amount amortized for the nine months ended September 30, 2011 was $38,272, resulting in a balance of $102,062 in accumulated amortization as of September 30, 2011. The balance of the intangible asset, net of accumulated amortization, is $408,248 as of September 30, 2011.

Upon closing of the asset sale by Resorbable NJ, the managers of this New Jersey limited liability company abandoned the name "Resorbable Orthopedic Products, LLC." RSI-ACQ Acquisition, LLC, a Texas limited liability company owned by the Company and formed on August 24, 2009, assumed the name of "Resorbable Orthopedic Products, LLC" in Texas.

The activity for the intangible accounts is summarized below:

	September 30, 2011			December 31, 2010
Patent	$	510,310		$	510,310
Accumulated amortization		(102,062	)		(63,790	)
Patent, net of accumulated amortization	$	408,248		$	446,520

Marketing contacts	$	4,187,815		$	4,187,815
Accumulated amortization		(837,563	)		(523,476	)
Marketing contacts, net of accumulated amortization	$	3,350,252		$	3,664,339
Total intangibles, net of accumulated amortization	$	3,758,500		$	4,110,859